CA2431374A1 - Novel fibroblast growth factors - Google Patents

Novel fibroblast growth factors Download PDF

Info

Publication number
CA2431374A1
CA2431374A1 CA002431374A CA2431374A CA2431374A1 CA 2431374 A1 CA2431374 A1 CA 2431374A1 CA 002431374 A CA002431374 A CA 002431374A CA 2431374 A CA2431374 A CA 2431374A CA 2431374 A1 CA2431374 A1 CA 2431374A1
Authority
CA
Canada
Prior art keywords
fgf
polypeptide
amino acid
nucleotide sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002431374A
Other languages
English (en)
French (fr)
Inventor
Peter W. Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2431374A1 publication Critical patent/CA2431374A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002431374A 2000-12-08 2001-12-10 Novel fibroblast growth factors Abandoned CA2431374A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US60/251,837 2000-12-08
US10/005,646 2001-12-07
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
CA2431374A1 true CA2431374A1 (en) 2002-06-13

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002431374A Abandoned CA2431374A1 (en) 2000-12-08 2001-12-10 Novel fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (cg-RX-API-DMAC7.html)
EP (1) EP1389237A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005506275A (cg-RX-API-DMAC7.html)
KR (1) KR20040052442A (cg-RX-API-DMAC7.html)
CN (1) CN1518597A (cg-RX-API-DMAC7.html)
AU (1) AU2603402A (cg-RX-API-DMAC7.html)
BG (1) BG107888A (cg-RX-API-DMAC7.html)
BR (1) BR0116507A (cg-RX-API-DMAC7.html)
CA (1) CA2431374A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031570A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300269A (cg-RX-API-DMAC7.html)
HU (1) HUP0400657A1 (cg-RX-API-DMAC7.html)
IL (1) IL156259A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005142A (cg-RX-API-DMAC7.html)
NO (1) NO20032573L (cg-RX-API-DMAC7.html)
PL (1) PL366158A1 (cg-RX-API-DMAC7.html)
RU (1) RU2329058C2 (cg-RX-API-DMAC7.html)
SI (1) SI21372A (cg-RX-API-DMAC7.html)
SK (1) SK7012003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002046424A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305236B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP1608411B1 (en) * 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
LT2726511T (lt) 2011-07-01 2019-11-11 Ngm Biopharmaceuticals Inc Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2003512841A (ja) * 1999-10-22 2003-04-08 カイロン コーポレイション ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物
JP2003516731A (ja) * 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
HUP0400657A1 (en) 2006-04-28
US20080057076A1 (en) 2008-03-06
ZA200305236B (en) 2005-06-29
SI21372A (sl) 2004-06-30
EP1389237A2 (en) 2004-02-18
RU2003119657A (ru) 2005-02-27
AU2002226034A2 (en) 2002-06-18
IL156259A0 (en) 2004-01-04
BR0116507A (pt) 2004-01-06
NO20032573D0 (no) 2003-06-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
CZ20031570A3 (cs) 2004-01-14
KR20040052442A (ko) 2004-06-23
BG107888A (bg) 2004-08-31
AU2603402A (en) 2002-06-18
US20020151496A1 (en) 2002-10-17
NO20032573L (no) 2003-07-22
WO2002046424A3 (en) 2003-11-27
EE200300269A (et) 2003-10-15
PL366158A1 (en) 2005-01-24
MXPA03005142A (es) 2004-10-15
SK7012003A3 (en) 2004-04-06
WO2002046424A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
US6447783B1 (en) Compositions comprising FGF9 and use thereof for stimulating cartilage and bone repair
JPH09510103A (ja) 線維芽細胞成長因子−１０
AU2010202764B2 (en) Single domain TDF-related compounds and analogs thereof
AU2002226034B2 (en) Fibroblast growth factors
AU2002226034A1 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
US6677117B1 (en) Human polyhomeotic 2 (hph2) acts as a tumor suppressor
WO2001032197A2 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
WO1998017798A1 (en) Placental-derived prostate growth factors
US7291483B2 (en) FGF-CX polynucleotide sequences and methods of producing same
HK1068648A (en) Novel fibroblast growth factors
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
CA2335326A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
JP2003509015A (ja) 新規な造血調節因子およびその使用方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued